吡啶-4-乙酸 | 28356-58-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 吡啶-4-乙酸
• 中文别名: 4-吡啶乙酸
• 英文名称: pyridine-4-acetic acid
• 英文别名: 4-Pyridylacetic acid；2-(pyridin-4-yl)acetic acid；4-pyridineacetic acid；2-pyridin-4-ylacetic acid
• CAS: 28356-58-3
• 化学式: C₇H₇NO₂
• 分子量: 137.138
• InChiKey: PAEXAIBDCHBNDC-UHFFFAOYSA-N

物化性质

• 熔点：
  139-141 C
• 沸点：
  303.8±17.0 °C(Predicted)
• 密度：
  1.245±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，未有已知危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S27,S28,S36,S36/37/39,S45
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933399090
• 危险品运输编号：
  UN 3263 8/PG 2
• 储存条件：
  请将贮藏器密封，并将其存放在阴凉、干燥处。同时，确保工作环境有良好的通风或排气装置。

SDS

Name:	4-Pyridylacetic Acid Hydrochloride 98% Material Safety Data Sheet
Synonym:	4-Pyridineacetic Acid
CAS:	28356-58-3

Section 1 - Chemical Product MSDS Name:4-Pyridylacetic Acid Hydrochloride 98% Material Safety Data Sheet
Synonym:4-Pyridineacetic Acid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
28356-58-3	4-Pyridylacetic Acid Hydrochloride	98%	248-990-5

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed.
Avoid ingestion and inhalation. Use with adequate ventilation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 28356-58-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 139.00 - 141.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H7NO2.HCl
Molecular Weight: 173.60

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents, acids, bases.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 28356-58-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Pyridylacetic Acid Hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
WGK (Water Danger/Protection)
CAS# 28356-58-3: No information available.
Canada
CAS# 28356-58-3 is listed on Canada's NDSL List.
CAS# 28356-58-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 28356-58-3 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  吡啶-4-乙酸 在 platinum(IV) oxide 、 palladium on activated charcoal 盐酸 、 sodium hydroxide 、 草酰氯 、 四溴化碳 、 硼烷 、 氢气 、 sodium hydride 、 sodium carbonate 、 二甲基亚砜 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 溶剂黄146 、 乙酸乙酯 、 乙腈 为溶剂， -78.0~25.0 ℃ 、379.21 kPa 条件下， 反应 230.33h， 生成 盐酸替罗非班
  参考文献：
  名称：

  Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp

  摘要：

  Inhibitors of platelet-fibrinogen binding offer an opportunity to interrupt the final, common pathway for platelet aggregation. Small molecule inhibitors of the platelet fibrinogen receptor GPIIb/IIIa were prepared and evaluated for their ability to prevent platelet aggregation. Compound 23m (L-700,462/MK-383) inhibited in vitro platelet aggregation with an IC50 of 9 nM and demonstrated a selectivity of > 24 000-fold between platelet and human umbilical vein endothelial cell fibrinogen receptors. Dose-dependent inhibition of ex vivo platelet aggregation induced by ADP was achieved with iv infusions of 0.1-10 mu g/kg/min of 23m in anesthetized dogs, with 10 mu g/kg/min completely inhibiting platelet aggregation during the entire 6 h infusion protocol. Platelet aggregatability returned rapidly after the termination of the 23m infusions. These features suggest that 23m may be useful in the treatment of arterial occlusive disorders.

  DOI：

  10.1021/jm00042a007
• 作为产物：
  描述：

  以 硫酸 为溶剂， 生成 吡啶-4-乙酸
  参考文献：
  名称：

  σ键合的有机过渡金属离子。第十一部分。吡啶甲基五氰基氨基钴酸根离子（III）与with（III），汞（II），铟（III）和氯化镓（III）在酸性水溶液中反应的动力学和机理

  摘要：

  铊的反应（的动力学和产品III）和汞（II）氯化物与2-，3-，和4- pyridiomethylpentacyanocobaltate（III）离子已被研究作为在酸水溶液中的氯离子浓度的函数。铊（III），氯化置换pentacyanocobaltate（III）基团，氯离子是否存在或不存在，以得到相应的monopyridiomethylthallium（III由双分子（）氯离子小号ë 2）的过程。氯化汞（II）取代了戊酸钴（III））仅在添加的氯离子存在下通过类似的反应进行分组。在不存在添加氯离子的情况下，并且在一定程度上在低浓度氯离子存在的情况下，氯化汞（II）有助于去除氰化物配体，从而生成大量的吡啶并二甲基-四氰基钴酸根（III）离子。对亲电子取代的反应性比吡啶基甲基戊酰氨基钴酸根离子（III）低。铟（III）和镓（III），氯化不与pyridiomethyl-pentacyanoc

  DOI：

  10.1039/j19700000517

文献信息

• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20090286778A1

  公开（公告）日：2009-11-19

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下化学式I的大环化合物： 或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
• [EN] COMPOUNDS USEFUL AS CSF1 MODULATORS<br/>[FR] COMPOSÉS UTILES EN TANT QUE MODULATEURS DU FACTEUR 1 DE STIMULATION DE COLONIES
  申请人：REDX PHARMA PLC

  公开号：WO2016051193A1

  公开（公告）日：2016-04-07

  This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.

  这项发明涉及新颖化合物以及包含这些新颖化合物的药物组合物。更具体地，该发明涉及用作集落刺激因子1受体（cFMS）调节剂（例如cFMS抑制剂）的化合物。这项发明还涉及制备这些化合物的方法，这些化合物在治疗中的用途以及利用这些化合物进行治疗的方法。具体而言，该发明涉及利用这些化合物治疗癌症和自身免疫性疾病。
• Discovery and Development of <i>N</i>-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H₃ Receptor Inverse Agonist with Robust Wake-Promoting Activity
  作者：Ramakrishna Nirogi、Anil Shinde、Abdul Rasheed Mohammed、Rajesh Kumar Badange、Veena Reballi、Thrinath Reddy Bandyala、Sangram Keshari Saraf、Kumar Bojja、Sravanthi Manchineella、Pramod Kumar Achanta、Kiran Kumar Kandukuri、Ramkumar Subramanian、Vijay Benade、Raghava Choudary Palacharla、Pradeep Jayarajan、Santoshkumar Pandey、Venkat Jasti

  DOI：10.1021/acs.jmedchem.8b01280

  日期：2019.2.14

  histamine H3 receptor (H3R), physicochemical properties, and pharmacokinetics in rats resulted in identification of N-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (17v, SUVN-G3031) as a clinical candidate. Compound 17v is a potent (hH3R Ki = 8.73 nM) inverse agonist at H3R with selectivity over other 70 targets, Compound 17v has adequate oral exposures and

  在大鼠中对组胺H3受体（H3R）的体外亲和力，理化性质和药代动力学指导下的一系列化学优化导致鉴定了N- [4-（1-环丁基-哌啶丁-4-基氧基）苯基] -2 -（吗啉-4-基）乙酰胺二盐酸盐（17v，SUVN-G3031）作为临床候选药物。化合物17v在H3R上是一种强效（hH3R Ki = 8.73 nM）反向激动剂，对其他70个靶标具有选择性。化合物17v在大鼠和狗中均具有足够的口服暴露量和良好的消除半衰期。它显示出高的受体占有率和明显的促醒作用，并减少了Orexin-B萨泊林损伤的大鼠的快速眼动睡眠，支持了其在治疗人类睡眠障碍中的潜在治疗作用。剂量比有效剂量高出几倍，对运动活性没有影响。它没有hERG和磷脂病的问题。已经成功完成了对动物的安全性，耐受性和药代动力学的第一阶段评估，以及对动物的长期安全性研究，而无需担心进一步的开发。
• [EN] COSMETIC USES AND METHODS FOR INDOLINE GRANZYME B INHIBITOR COMPOSITIONS<br/>[FR] UTILISATIONS ET PROCÉDÉS COSMÉTIQUES POUR DES COMPOSITIONS D'INHIBITEUR D'INDOLINE GRANZYME B
  申请人：VIDA THERAPEUTICS INC

  公开号：WO2014153667A1

  公开（公告）日：2014-10-02

  Cosmetic uses and methods for indoline granzyme B inhibitor compounds in compositions with a cosmetically acceptable carrier. Uses and methods for treating, reducing or inhibiting the appearance of ageing in the skin are provided. Also provided are compositions and formulation for cosmetic uses and methods of maintaining a youthful appearance, reducing an appearance of ageing, inhibiting an appearance of ageing, reducing a rate of an appearance of ageing, reducing a skin inelasticity, reducing a rate of increasing skin inelasticity, maintaining a skin elasticity, and increasing the density of hair follicles of a skin of a subjecl. The uses and methods comprise applying/administering an indoline granzyme B inhibitor to a skin, or a portion of a skin of the subject.

  使用和方法用于在与化妆品可接受载体混合的化合物中使用吲哚啶颗粒酶B抑制剂。提供了用于治疗、减少或抑制皮肤衰老的用途和方法。还提供了用于化妆品用途的组合物和配方，以及保持年轻外观、减少衰老外观、抑制衰老外观、减少衰老外观速率、减少皮肤无弹性、减少增加皮肤无弹性速率、保持皮肤弹性和增加皮肤毛囊密度的方法。这些用途和方法包括将吲哚啶颗粒酶B抑制剂涂抹/施用于皮肤或受试者皮肤的部分。
• Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i)
  作者：Markus Klein、Michael Busch、Manja Friese-Hamim、Stefano Crosignani、Thomas Fuchss、Djordje Musil、Felix Rohdich、Michael P. Sanderson、Jeyaprakashnarayanan Seenisamy、Gina Walter-Bausch、Ugo Zanelli、Philip Hewitt、Christina Esdar、Oliver Schadt

  DOI：10.1021/acs.jmedchem.1c00604

  日期：2021.7.22

  acids, which selectively inhibit LMP7 while sparing all other subunits. The exploitation of structural differences between the proteasome subunits culminated in the identification of the highly potent, exquisitely selective, and orally available LMP7 inhibitor 50 (M3258). Based on the strong antitumor activity observed with M3258 in MM models and a favorable preclinical data package, a phase I clinical

  蛋白酶体是泛素依赖性蛋白质降解途径中广泛表达的关键成分，其中包含具有催化活性的亚基（β1、β2 和 β5）。LMP7 (β5i) 是免疫蛋白酶体的一个亚基，是一种主要在造血细胞中表达的诱导型异构体。用于治疗多发性骨髓瘤 (MM) 的临床有效的泛蛋白酶体抑制剂非选择性靶向 LMP7 和组成型蛋白酶体和免疫蛋白酶体的其他亚基，具有相当的效力，这可能会限制这些药物的治疗适用性。在这里，我们描述了新型酰氨基硼酸的发现和基于结构的命中优化，它选择性地抑制 LMP7，同时保留所有其他亚基。对蛋白酶体亚基之间结构差异的开发最终确定了高效能，50 (M3258)。基于 M3258 在 MM 模型中观察到的强大抗肿瘤活性和有利的临床前数据包，在复发/难治性 MM 患者中启动了 I 期临床试验。